OBJECTIVE: Cyclo-oxygenase-2 seems to be involved at various steps in the processes of tumor progression. The objective of this study was to examine the relationship between cyclo-oxygenase-2 expression and tumor proliferation, apoptosis and angiogenesis in patients with advanced stage high-grade ovarian carcinoma. STUDY DESIGN: Specimens from 118 patients with high-grade and advanced stage (III, IV) serous ovarian carcinoma were evaluated by immunohistochemistry for cyclo-oxygenase-2, Ki-67, vascular endothelial growth factor, and bcl-2 expression. Tumor microvessel density was assessed with CD34 immunostaining. We investigated the relationships between cyclo-oxygenase-2 expression and clinicopathologic characteristics, tumor angiogenesis (tumor microvessel density and vascular endothelial growth factor expression), and tumor proliferation and apoptosis. The effect of cyclooxygenase-2 expression on patient survival was determined. RESULTS: There was a significant positive correlation between cyclo-oxygenase-2 expression in tumor cells and markers of tumor proliferation and angiogenesis. In univariate survival analysis, high cyclo-oxygenase-2 and high Ki-67 expression showed a significant impact of on patient survival (P < .001). In multivariate regression analysis, only Ki-67 expression retained its significance as an independent poor prognostic factor (death hazard ratio, 2.0; 95% CI, 1.2-3.3; P < .001). CONCLUSION: Expression of cyclo-oxygenase-2 correlates with tumor proliferation and tumor angiogenesis but not with apoptotic markers (bcl-2 expression) in high-grade, advanced-stage serous ovarian carcinoma.
OBJECTIVE:Cyclo-oxygenase-2 seems to be involved at various steps in the processes of tumor progression. The objective of this study was to examine the relationship between cyclo-oxygenase-2 expression and tumor proliferation, apoptosis and angiogenesis in patients with advanced stage high-grade ovarian carcinoma. STUDY DESIGN: Specimens from 118 patients with high-grade and advanced stage (III, IV) serous ovarian carcinoma were evaluated by immunohistochemistry for cyclo-oxygenase-2, Ki-67, vascular endothelial growth factor, and bcl-2 expression. Tumor microvessel density was assessed with CD34 immunostaining. We investigated the relationships between cyclo-oxygenase-2 expression and clinicopathologic characteristics, tumor angiogenesis (tumor microvessel density and vascular endothelial growth factor expression), and tumor proliferation and apoptosis. The effect of cyclooxygenase-2 expression on patient survival was determined. RESULTS: There was a significant positive correlation between cyclo-oxygenase-2 expression in tumor cells and markers of tumor proliferation and angiogenesis. In univariate survival analysis, high cyclo-oxygenase-2 and high Ki-67 expression showed a significant impact of on patient survival (P < .001). In multivariate regression analysis, only Ki-67 expression retained its significance as an independent poor prognostic factor (death hazard ratio, 2.0; 95% CI, 1.2-3.3; P < .001). CONCLUSION: Expression of cyclo-oxygenase-2 correlates with tumor proliferation and tumor angiogenesis but not with apoptotic markers (bcl-2 expression) in high-grade, advanced-stage serous ovarian carcinoma.
Authors: Bastian Czogalla; Christina Kuhn; Sabine Heublein; Elisa Schmöckel; Doris Mayr; Thomas Kolben; Fabian Trillsch; Alexander Burges; Sven Mahner; Udo Jeschke; Anna Hester Journal: J Cancer Res Clin Oncol Date: 2019-09-04 Impact factor: 4.553
Authors: Jie Huang; Wei Hu; Justin Bottsford-Miller; Tao Liu; Hee Dong Han; Behrouz Zand; Sunila Pradeep; Ju-Won Roh; Duangmani Thanapprapasr; Heather J Dalton; Chad V Pecot; Rajesh Rupaimoole; Chunhua Lu; Bryan Fellman; Diana Urbauer; Yu Kang; Nicholas B Jennings; Li Huang; Michael T Deavers; Russell Broaddus; Robert L Coleman; Anil K Sood Journal: Clin Cancer Res Date: 2014-01-31 Impact factor: 12.531
Authors: Chunhua Lu; Hee Dong Han; Lingegowda S Mangala; Rouba Ali-Fehmi; Christopher S Newton; Laurent Ozbun; Guillermo N Armaiz-Pena; Wei Hu; Rebecca L Stone; Adnan Munkarah; Murali K Ravoori; Mian M K Shahzad; Jeong-Won Lee; Edna Mora; Robert R Langley; Amy R Carroll; Koji Matsuo; Whitney A Spannuth; Rosemarie Schmandt; Nicholas B Jennings; Blake W Goodman; Robert B Jaffe; Alpa M Nick; Hye Sun Kim; Eylem Ozturk Guven; Ya-Huey Chen; Long-Yuan Li; Ming-Chuan Hsu; Robert L Coleman; George A Calin; Emir B Denkbas; Jae Yun Lim; Ju-Seog Lee; Vikas Kundra; Michael J Birrer; Mien-Chie Hung; Gabriel Lopez-Berestein; Anil K Sood Journal: Cancer Cell Date: 2010-08-09 Impact factor: 31.743
Authors: Simone P Pinheiro; Shelley S Tworoger; Daniel W Cramer; Bernard A Rosner; Susan E Hankinson Journal: Am J Epidemiol Date: 2009-04-02 Impact factor: 4.897
Authors: Mollie E Barnard; Alicia Beeghly-Fadiel; Ginger L Milne; Eftitan Y Akam; Andrew T Chan; A Heather Eliassen; Bernard A Rosner; Xiao-Ou Shu; Kathryn L Terry; Yong-Bing Xiang; Wei Zheng; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-08-06 Impact factor: 4.254